

December 18, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Completion of US FDA Inspection at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the Company – Reg.,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that –

The United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from December 08 to December 17, 2025.

At the end of the current inspection, a 'Form 483' was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines.

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl.: Annexure

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

S.No	Particulars	Details
1.	Name of the authority	US Food and Drug Administration (US FDA), USA
2.	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	US FDA inspected Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh. from December 08 to December 17, 2025.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	December 17, 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	At the end of the current inspection, a 'Form 483' was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines.
5.	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	This development doesn't have any impact on financials & operations of the facility.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivi Har, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com